Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ricinus communis is a medicinal plant commonly known as castor bean or castor oil plant. The primary bioactive components found in different parts of the plant include ricinoleic acid, ricin (a potent ribosome-inactivating protein toxalbumin), ricinine (an alkaloid), and various flavonoids, saponins, terpenoids, and glycosides. Traditionally, it has been used for its **laxative**, **anti-inflammatory**, **antimicrobial**, **antioxidant**, **analgesic**, **anticancer**, **antidiabetic**, **anthelmintic**, and **wound-healing** properties[1][2][3][4][5][6]. Its medicinal effects are exerted through various mechanisms, notably ricinoleic acid (from seed oil) acting as a potent purgative via stimulation of intestinal and uterine smooth muscle (prostaglandin EP3 receptor agonism)[5], as well as the direct anti-inflammatory and cytotoxic activities of plant extracts and isolated components (such as ricin). The **castor oil** derived from the seeds is used safely internally and externally, whereas whole seeds are highly toxic due to ricin. Ricin itself has been explored as a protein toxin component for targeted cancer therapies (immunotoxins), but is notoriously poisonous if ingested or improperly handled[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ricinus communis.